Exploring the RANK–RANKL–OPG axis in MASLD enhances our understanding of the disease and opens up promising avenues for therapeutic interventions across hepatology, endocrinology, and bone metabolism. This evidence concerns the gene TNFRSF11A and metabolic dysfunction-associated steatotic liver disease.